Mycobacterial immunotherapy for treating cancer
AssigneeImmodulon Therapeutics Limited
InventorsGLEN MARTYN, JAKOB KAMPINGA, THOMAS KLEEN
Life of this patent
Estimating the term…
Abstract
This invention provides an immunomodulator for use in the adjuvant, neoadjuvant or peri-adjuvant treatment, reduction, inhibition or control of cancer in patients that have undergone, or are intended to undergo, tumour resection surgery and/or one or more additional anticancer treatments or agents, preferably checkpoint inhibitor therapy. The invention also describes the use of one or more additional anticancer treatments or agents in the adjuvant, neoadjuvant or peri-adjuvant setting, as well as protocols and dosage regimens for use.
Claims17
1-37. (canceled)
A method of treating or controlling cancer comprising a primary tumour in a patient that has undergone, or is intended to undergo, tumour resection surgery, wherein said method comprises simultaneously, separately or sequentially administering to the subject, (i) a non-pathogenic non-viable Mycobacterium, (ii) tumour resection surgery, and (iii) one or more additional anticancer treatments or agents, wherein said method results in enhanced therapeutic efficacy relative to administration of non-pathogenic non-viable Mycobacterium, administration of one or more additional anticancer treatments or agents, or tumour resection surgery alone.
Dependencies are inferred from the claim text.